The Food and Drug Administration (FDA) on Wednesday approved the first gene therapy treatment that could offer a permanent cure for patients who suffer from a rare blood disorder, which the manufacturer priced at $2.8 million per patient. The cost would make the therapy one of the most expensive treatments of all time. The therapy was developed by bluebird bio and will be sold under the brand name Zynteglo. It offers a treatment for beta-thalassemia, a type of inherited blood disorder that causes a reduction of normal hemoglobin, a protein in red blood cells that carries oxygen through the body. The reduced levels of hemoglobin can lead to a number of health issues including di
Hence then, the article about fda approves 2 8m gene therapy treatment for rare blood disorder was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( FDA approves $2.8m gene therapy treatment for rare blood disorder )